Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Synlogic Yönetim

Yönetim kriter kontrolleri 3/4

Synlogic's CEO'su Tony Awad, Mar2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 701.53K olup, şirket hissesi ve opsiyonları dahil olmak üzere 60.3% maaş ve 39.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.29% ine doğrudan sahiptir ve bu hisseler $ 50.45K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 7.9 yıldır.

Anahtar bilgiler

Tony Awad

İcra Kurulu Başkanı

US$701.5k

Toplam tazminat

CEO maaş yüzdesi	60.3%
CEO görev süresi	less than a year
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Sep 06

Synlogic's metabolic disorder drug gets FDA fast track status

Aug 23

Synlogic Q2 2022 Earnings Preview

Aug 10

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Aug 09

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Jul 12

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Jan 11

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Sep 28

Synlogic (SYBX) Investor Presentation - Slideshow

Jun 08

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Jun 03

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Feb 23

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

Jan 19

Synlogic outlines clinical milestones for 2021

Jan 11

Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary

Dec 15

Synlogic, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Synlogic EPS beats by $0.10

Nov 05

CEO Tazminat Analizi

Tony Awad'un ücretlendirmesi Synlogic'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$73m
Dec 31 2023	US$702k	US$423k	-US$57m
Sep 30 2023	n/a	n/a	-US$59m
Jun 30 2023	n/a	n/a	-US$65m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$876k	US$411k	-US$66m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$811k	US$391k	-US$61m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$57m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$723k	US$359k	-US$59m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$57m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$809k	US$325k	-US$51m

Tazminat ve Piyasa: Tony 'ın toplam tazminatı ($USD 701.53K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 677.23K ).

Tazminat ve Kazançlar: Tony 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tony Awad (44 yo)

less than a year

Görev süresi

US$701,534

Tazminat

Mr. Antoine Awad, also known as Tony, served as Chief Operating Officer at Synlogic, Inc. since July 2020 and was its Head of Technical Operations since December 12, 2018 until 2020 and serves as Principal...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Antoine Awad	Principal Executive Officer	less than a year	US$701.53k	0.29% $ 51.5k
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mary Dooley	VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer	less than a year	Veri yok	0.13% $ 23.2k
Ajay Munshi	Vice President of Corporate Development	no data	Veri yok	Veri yok
Molly Harper	Chief Business Officer	3.1yrs	Veri yok	Veri yok
Neal Sondheimer	VP & Head of Clinical	1.3yrs	Veri yok	Veri yok
Mylene Perreault	VP & Head of Research	1.8yrs	Veri yok	Veri yok
Jose-Carlos Gutierrez-Ramos	Advisor	no data	US$1.39m	Veri yok

1.3yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: SYBX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Timothy Lu	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Collins	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Shea	Independent Director	7.2yrs	US$65.70k	0.0043% $ 760.3
Peter Barrett	Independent Chairman of the Board	10.3yrs	US$92.20k	0% $ 0
Edward Mathers	Independent Director	12yrs	US$55.70k	0% $ 0
Michael Heffernan	Independent Director	3.8yrs	US$66.20k	0% $ 0
Nick Leschly	Independent Director	8.6yrs	US$55.70k	0.013% $ 2.3k
Paul Miller	Member Scientific Advisory Board	no data	US$956.81k	Veri yok
Kristala Lanett Prather	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Cammie Lesser	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Christopher Voigt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Flynn	Independent Director	less than a year	Veri yok	Veri yok

7.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SYBX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Synlogic Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Recent updates

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Price target decreased by 96% to US$1.00

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Consensus revenue estimates increase by 747%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$11.03 loss

New major risk - Revenue and earnings growth

Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?

Price target decreased by 11% to US$5.00

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Consensus revenue estimates increase by 11%, EPS downgraded

We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate

Consensus EPS estimates fall by 11%

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Consensus forecasts updated

Synlogic Therapeutics: SYNB1934 Advances To Phase 3

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Synlogic's metabolic disorder drug gets FDA fast track status

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Q2 2022 Earnings Preview

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Consensus forecasts updated

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$8.00

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Price target decreased to US$9.00

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Price target increased to US$10.00

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Consensus revenue estimates increase to US$389.7k

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic (SYBX) Investor Presentation - Slideshow

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Price target increased to US$10.00

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Synlogic Appoints Lisa Kelly-Croswell to Its Board of Directors

New 90-day high: US$4.90

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

New 90-day high: US$3.18